P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...

Omalizumab is highly effective and safe for the treatment for CSU as well as for "chronic inducible urticaria," which is seen in the remaining 20% of patients with chronic urticaria. Omalizumab ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

The best way to treat hives is to avoid ... the-counter drugs like antihistamines and H2 blockers. Chronic or ...

The mainstay of treatment for urticaria is oral ... especially in aspirin-sensitive urticaria. Nifedipine has a small effect in chronic urticaria, and is often used for patients with concomitant ...

THE cold weather can trigger a range of symptoms, with the most common being shivering. But if certain symptoms seem out of ...

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a successor have seen some ...

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...

From the perspective of society, treatment with levocetirizine was cost saving, with a net gain of €91.93 per patient per month. Conclusion: Treating chronic idiopathic urticaria with ...

Analyst Etzer Darout from BMO Capital reiterated a Buy rating on Jasper Therapeutics (JSPR – Research Report) and keeping the price target at ...

Citi keeps a Buy rating on Celldex (CLDX) with a $70 price target after after Jasper Therapeutics (JSPR) reported preliminary data from its ...